There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Cardiome Pharma Corp (NASDAQ: CRME), Cara Therapeutics (NASDAQ: CARA) and Kamada (NASDAQ: KMDA) with bullish sentiments.
Cardiome Pharma Corp (NASDAQ: CRME)
H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating on Cardiome Pharma Corp (NASDAQ: CRME) today and set a price target of $9.50. The company’s shares opened today at $3.63.
According to TipRanks.com, Ramakanth is ranked 0 out of 5 stars with an average return of -18.0% and a 25.6% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as X T L Biopharmaceuticals Ltd (ADR), Strata Skin Sciences Inc, and Spectrum Pharmaceuticals.
Cardiome Pharma Corp has an analyst consensus of Moderate Buy, with a price target consensus of $9.25.
Cara Therapeutics (NASDAQ: CARA)
In a report released today, Corey Davis from H.C. Wainwright reiterated a Buy rating on Cara Therapeutics (NASDAQ: CARA), with a price target of $30. The company’s shares opened today at $15.59.
Davis said:
“Cara held an analyst day on Tuesday to talk more about its previously released P2 pruritus data. Even though this occured right before the results of its ongoing two pain studies (expected by the company in June), we think Cara wanted to ensure the Street was well versed in the pruritus data before the other studies come out in very different settings. We think the current valuation (~$544M market cap) can be supported by an indication in pruritus alone, even though we expect positive outcomes in both of the pain studies based on all the previous positive data and based on the common pathways between pain and pruritus. Cara took the opportunity to rehash much of the data it previously released on March 28, but it revealed two new pieces of information (and several other ancillary tidbits) that we found particularly intriguing: 1. Inflammation.”
According to TipRanks.com, Davis is a 1-star analyst with an average return of -0.7% and a 44.1% success rate. Davis covers the Healthcare sector, focusing on stocks such as Aquinox Pharmaceuticals, Infotek Pharmaceuticals, and Zynerba Pharmaceuticals.
Currently, the analyst consensus on Cara Therapeutics is Strong Buy and the average price target is $27, representing a 73.2% upside.
In a report issued on May 5, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $25 price target.
Kamada (NASDAQ: KMDA)
In a report released today, Andrew Fein from H.C. Wainwright reiterated a Buy rating on Kamada (NASDAQ: KMDA), with a price target of $10. The company’s shares opened today at $6.95, close to its 52-week high of $7.34.
According to TipRanks.com, Fein is a 4-star analyst with an average return of 7.7% and a 49.3% success rate. Fein covers the Healthcare sector, focusing on stocks such as Neptune Technologies & Bioresources Inc, DBV Technologies SA – American, and Proteostasis Therapeutics Inc.
Currently, the analyst consensus on Kamada is Moderate Buy and the average price target is $9.50, representing a 36.7% upside.
In a report released yesterday, Jefferies also reiterated a Buy rating on the stock with a $9 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.